The Postnatal Lung Maturation Disrupted by Increased Pulmonary Blood Flow and Its Clinical Implications
This study establishes the first neonatal IPF model and identifies actionable therapeutic targets, including immune modulators (NLRP3/IL23R inhibitors), cell cycle regulators (Birc5/CENPE agonists), and neural/circadian mediators (Nr1d1/Per2 activators). These findings provide a roadmap for mitigating IPF-driven lung maldevelopment.
Authors
- Sixie Zheng (ORCID: https://orcid.org/0000-0001-6603-7947)
- Yingying Xiao (ORCID: https://orcid.org/0000-0003-4192-013X)
- Lincai Ye (ORCID: https://orcid.org/0000-0001-8808-2810)
- He Zhang (ORCID: https://orcid.org/0000-0002-4572-8420)
- Lisheng Qiu
- Debao Li
- Yiting Xue
- Yuqing Hu
- Qing Cui
- Chenxi Liu
- Jing Wang
- Zheng Wang
Institutions
- Ningbo University (CN)
- Shanghai Jiao Tong University (CN)
- Shanghai Children's Medical Center (CN)
- Children's Hospital of Fudan University (CN)
- Shanghai Children's Hospital (CN)
Publication Details
- Journal
- JACC Asia
- Published
- 2026-03-01
- DOI
- https://doi.org/10.1016/j.jacasi.2026.02.013
- Primary Topic
- Neonatal Respiratory Health Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00